Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Famitinib + camrelizumab + TP chemotherapy as neoadjuvant therapy for locally advanced cervical cancer
ChiCTR2500109134Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of famitinib and camrelizumab in Cervical Cancer (CC), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Pathological complete response. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
famitinibcamrelizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2500109134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109134.